Search | Invivogen

VET-SAP® saponin adjuvant

Saponin vaccine adjuvant - CAS #8047-15-2

Default product image

#TLR7/8 Ligands

R848 (Resiquimod) - TLR7/8 Agonist

Imidazoquinoline compound - CAS #144875-48-9

NF-κB response of HEK-Blue™-derived cells to R848

NF-κB and IRF responses of THP1-Dual™-derived cells to R848

R848 chemical structure

2’3’-cGAM(PS)2 (Rp/Sp) - STING Agonist

Bisphosphorothioate analog of 2'3'-cGAMP, (Rp/Sp) cyclic [G(2’,5’)psA(3’,5’)ps]

IRF INDUCTION (Lucia luciferase reporter)

NF-kB INDUCTION (SEAP reporter)

2’3’-cGAM(PS)2 (Rp/Sp) structure

3'3'-cGAMP Fluorinated - STING Agonist

Difluoro 3'3'-cGAMP, cyclic [FdG(3’,5’)pFdA(3’,5’)p]

IRF INDUCTION (Lucia luciferase reporter)

NF-kB INDUCTION (SEAP reporter)

3'3'-cGAMP Fluorinated structure

2'3'-cGAMP VacciGrade™ - STING-based Adjuvant

Mammalian (non-canonical) CDN - Cyclic [G(2’,5’)pA(3’,5’)p] | Th1/Th2 response

IRF INDUCTION (Lucia luciferase reporter)

NF-kB INDUCTION (SEAP reporter)

2'3'-cGAMP - STING Agonist

Mammalian (non-canonical) CDN, cyclic [G(2’,5’)pA(3’,5’)p]

IRF INDUCTION (Lucia luciferase reporter)

NF-kB INDUCTION (SEAP reporter)

CL429 VacciGrade™ - TLR2 & NOD2-based Adjuvant

Pam2C-conjugated murabutide

Dose-dependent NF-κB response to CL429 in HEK-Blue™ hTLR2 and HEK-Blue™ hNOD2 cells

CL429 chemical structure

Pam3CSK4 VacciGrade™ - TLR2/TLR1-based Adjuvant

Synthetic triacylated lipopeptide | Th1 response

Evaluation of NF-κB activation with Pam3CSK4

Specificity of Pam3CSK4 activation

ODN 1585 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class A (Mouse) | Th1 response

Dose-dependent NF-κB response of ODN 1585 in HEK-Blue™ mTLR9 cells

NF-κB and IRF responses of ODN 1585 in THP1-Dual™ hTLR9 cells

CL413 VacciGrade™ - TLR2 & TLR7-based Adjuvant

Chimeric molecule | Th1/Th2 response

Tumor growth after CL413 or CL401 treatment

Survival curves for untreated as well as CL413- or CL401-treated mice

CL413 chemical structure

CL401 VacciGrade™ - TLR2 & TLR7-based Adjuvant

Pam2C-conjugated 8-hydroxyadenine| Th1/Th2 response

Tumor growth after CL413 or CL401 treatment

Survival curves for untreated as well as CL413- or CL401-treated mice

Anti-OVA mIgG levels at 15, 30 and 45 days after the initial immunization in different groups.

Anti-OVA total IgG, IgG1, and IgG2a levels 45 days after the initial immunization in different groups.

#TLR7/8 Ligands

TL8-506 - TLR8 Agonist

Benzo-azepine analog - CAS #1268163-15-0

NF-κB response of HEK-Blue™-derived cells to TL8-506

NF-κB and IRF responses of THP1-Dual™-derived cells to TL8-506

Quil-A® adjuvant

Saponin vaccine adjuvant

Default product image

c-di-AMP VacciGrade™ - STING-based Adjuvant

Cyclic diadenylate monophosphate | Th1/Th2 response

IRF INDUCTION (Lucia luciferase reporter)

NF-kB INDUCTION (SEAP reporter)

LPS-EB VacciGrade™ - TLR4-based Adjuvant

Lipopolysaccharide from E. coli 0111:B4 | Th1 response

LPS-EB Vaccigrade™-dependent activation of TLR4

TDB VacciGrade™ - Mincle-based Adjuvant

Synthetic analog of the cord factor | Th1 response

TDB dose-dependent activation of Mincle

ODN 2395 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class C (Human/mouse) | Th1 response

NF-κB response in HEK-Blue™-derived cells upon ODN 2395 stimulation

NF-κB and IRF response upon ODN 2395 stimulation

c-di-GMP VacciGrade™ - STING-based Adjuvant

Cyclic diguanylate monophosphate | Th1/Th2 response

IRF INDUCTION (Lucia luciferase reporter)

NF-kB INDUCTION (SEAP reporter)

CFA

Complete Freund’s Adjuvant | Th1 response

Anti-Ova mIgG levels at 15 and 30 days after the initial immunization with CFA

3'3'-cGAMP - STING Agonist

Bacterial (canonical) CDN, cyclic [G(3’,5’)pA(3’,5’)p]

IRF INDUCTION (Lucia luciferase reporter)

NF-kB INDUCTION (SEAP reporter)